

REFERENCES

- Aarnoutse RE, Grintjes K, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose zidovudine in healthy volunteers. *Clin Pharmacol Ther* 2002;71:57-67.
- Adkins JC and Noble S. Efavirenz. *Drugs* 1998; 56:1055-64.
- Balani SK, Kauffman LR and Lin JH. Pharmacokinetics of L-743,726 (DMP-266), an HIV-1 reverse transcriptase inhibitor, in rats and monkeys (abstract). 7th North American ISSX Meeting, October 20, 1996; 10:268.
- Belitsos PC, Greenson JK, Yardly JH, et al. Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS. *J Infect Dis* 1992;166:277-84.
- Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetics (PK) interaction studies in healthy volunteers with efavirenz (EFV) and the macrolide antibiotics, azithromycin (AZM) and clarithromycin (CLR). 5th Conference on Retroviruses and Opportunistic Infection, Chicago, February 1998, Poster 347.
- Bennett JE, 1996. Antifungal agents. In : Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed., Hardman et al., eds., pp 1175-90, New York, Pergamon Press.

Berruet N, Sentenac S, Auchere D, et al. Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. *J Pharm Pharmaceut Sci* 2005;8:226-34.

Berry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions and amongst antiretroviral agents used to treat HIV infection. *Clin Pharmacokinet* 1999;36:289-304.

Brass C, Galgiani JN, Blaschke TF, et al. Disposition of ketoconazole, an oral antifungal, in human. *Antimicrob Agents Chemother* 1982;21:151-8.

Brown CH. Overview of drug interactions modulated by cytochrome P450. *US Pharm* 2001;26:3-16.

Carlson JA, Mann HJ and Canfax DM. Effect of pH on desintegration and dissolution of ketoconazole tablets. *Am J Hosp Pharm* 1983;40:1334-6.

Cartledge JD, Midgley J, Petrou M, et al. Unresponsive HIV-related oro-esophageal candidiasis an evaluation of two new *in vitro* azole susceptibility test. *J Antimicrob Chemother* 1997; 40:517-23.

CATIE 2003. A practical guide to HAART for people living with HIV/AIDS. (eds: Pustil R), 1st ed, pp 5-7, Toronto, Canada.

Chen H, Chen W, Gan LS, et al. Metabolism of (S)-5,6-difluoro-4-Cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1*H*)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsome. Metabolic activation and enzyme kinetics. *Drug Metab Dispos* 2003;31:122-32.

Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. *Br J Clin Pharmacol* 2001;51:213-7.

Clyti E, Sayavong K, Monchy D, et al. Penicilliosis in Laos. *Presse Med.* 2006 ;35:427-9.

Como JA and Dismukes WE. Oral azole drugs as systemic antifungal therapy. *N Eng J Med* 1994;330:263-72.

Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naïve Antiretroviral study. *J Infect Dis* 2002;185:1062-9.

=

Cupp MJ and Tracy TS. Cytochrome P450:New nomenclature and clinical Implications. *American Family Physician* 1998;57:107-117.

Dailly E, Allavena C, Raffi F, et al. Pharmacokinetic evidence of the induction of lopinavir metabolism by efavirenz. *Br J Clin Pharmacol* 2005;60:32-4.

Damle BD, Mummaneni V, Kaul S, et al. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. *Antimicrob Agents Chemother* 2002;46:385-91.

Daneshmend TK. Diseases and drugs but not food decrease ketoconazole bioavailability . *Br J Clin Pharmacol* 1990;29:783-4.

Daneshmend TK and Warnock DW. Clinical pharmacokinetics of ketoconazole. *Clin Pharmacokinet* 1988;14:13-34.

Deeks SG: Antiretroviral agents: the next generation (review). *AIDS Clin Care* 1998; 10:33-40.

Dismukes WE, Stamm AM, Graybill JR, et al. Treatment of systemic mycoses with ketoconazole : emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. *Am Intern Med* 1983;98:13-20.

US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. *MMWR* 2006.

—

Falloon J, Piscitelli S, Vogel S, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen : pharmacokinetics drug interaction and antiviral activity. *Clin Infect Dis* 2000;30:313-8.

Fogelman I, Lim L, Bassett R, et al. Prevalence and patterns of concomitant medications among participants in 3 multicentre HIV type 1 clinical trials. *J Acq Immune Def Syndrome* 1994;7: 1057-63.

Gascoigne EW, Barton GJ, Michaels M, et al. The kinetics of ketoconazole in animals and man. *Clin Res Rev* 1981;1:177-87.

Gazzard B, Moyle G, on behalf of the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. *Lancet* 1998; 352: 314-316.

Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin : results of AIDS Clinical Trials Group 5108 Study. *J Acquir Immune Defic Syndr* 2005;39(3):307-12.

Gibson GG, Plant NJ, Swales KE, Ayrton A, and El Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. *Xenobiotica* 2002; 32:165–206.

Glick M, Muzyka BC, Lurie D, et al. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. *Oral Surgery, Oral Medicine, and Oral Pathology* 1994;77:344-5.

Gonzalez FJ. Human cytochrome P450 : Problems and prospects. *Trends Pharmacol Sci* 1992;13:346-52.

Graybill JR and Duuzt DJ. Ketoconazole: A major innovation for treatment of fungal disease. *Ann Intern Med* 1980;93:921-3.

Greenspan D, Greenspan JS, Schiodt M, et al. eds: *AIDS and the mouth* 1990, pp 85-90, Copenhagen, Munksgaard.

Greenspan D. Treatment of oropharyngeal candidosis in HIV-infected patients. *J Am Acad Dermatol* 1994;31:S51-5.

Guengerich FP. Cytochrome P450 enzymes. *Am Scientist* 1993;81:440-7.

Guengerich FP. Cytochrome P4503A4: regulation and role in drug metabolism. *Annu Rev Pharmacol Toxicol* 1999;39:1-17.

Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampicin and phenobarbital. *J Clin Pharmacol* 2004;44:1273-81.

Heel RC, Brogden RN, Carmine A, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. *Drugs* 1982;23, 1-36.

Honkakoski P and Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. *Biochem. J* 2000;347:321-37.

Hospenthal DR and Bennett JE 2000. Miscellaneous fungi and protozoa In: Principle of practice of infection disease, (eds. Mandell GL, Bennett JE and Dolin R), 5th ed, p 2774, Philadelphia : Churchill Livingstone.

Hsian Y, Ding J, Das K, et al. Structure of unliganded HIV-1 reverse transcriptase at 2.7^oA resolution :implications of conformational changes for polymerization and inhibition mechanisms. *Structure* 1996;4:853-60.

Huang YC, Colaizzi JL, Bierman RH, et al. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. *Antimicrob Agents Chemther* 1986;30:206-10.

Johnson EF, Palmer CNA, Griffin KJ, Hsu MH. Role of the peroxisome proliferator-activated receptor in cytochrome P 4504A gene regulation. *FASEB J* 1996;10:1241-8.

Joshi AS, Fiske WD, Benedek IH, et al. Lack of pharmacokinetics interaction between

efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers. 5th Conference on Retroviruses and Opportunistic Infection, Chicago, February 1998, Poster 348.

Keiser P, Nasser N, White C, et al. Comparison of nevirapine- and efavirenz- containing antiretroviral regimen in antiretroviral-naïve patients:a cohort study. HIV Clin Trials 2002;3:296-303.

Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984;311:354–8.

Kliwer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXR: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res 1999;54:345–67.

Labbe L, Sheiner LB, Smith PF, et al. Effect of co-administration of efavirenz on the pharmacokinetics of nelfinavir and its active metabolite, M8 in ACTG 384. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Canada, April 2005, Abstract 22.

Lake-Bakaar G, Elsagr M, Haqqaq N, et al. Changes in parietal cell structure and function in HIV disease. Diag Dis Sci 1996; 41:1398-408.

Lambert H, O'Gardy FW. Antifungal agents. In: Lambert H, O'Gardy FW, eds. Antibiotics and chemotherapy. London: Churchill Livingstone, 1992:27-37.

Lamson M, Robinson P, Gigliotti M, et al. The pharmacokinetic interaction of nevirapine

and ketoconazole. 12th World AIDS Conference, Geneva, June 1998. Abstract 12218.

Leth F, Huisman CB, Badaro R, et al. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drug combined and is not predictive of long-term virology efficacy : A 2NN study. *J Acquir Immune Defic Syndr* 2005;38:296-300.

Lewis JH, Zimmerman HJ and Benton GD. Hepatic injury associated with ketoconazole therapy : Analysis of 33 cases. *Gastroenterology* 1984;86:503-13.

Liu P, Foster G, Labadie R, et al. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy subjects. *Clin Pharmacol Ther* 2005;77:40.

Lyman CA and Walsh TJ. Systemically administered antifungal agents: A review of their clinical pharmacology and therapeutic applications. *Drugs* 1992;44:9-35.

Lythgo PA. Molecular virology of HIV-1 and current antiviral strategies. *Bio Teach J* 2004;2:81-7.

Ma YM, Ma ZQ, Gui CQ, et al. Hepatotoxicity and toxicokinetics of ketoconazole in rabbits. *Acta Pharmacol Sin* 2003;24:778-82.

Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment

failure and central nervous system side effects in HIV-1-infected patients. *AIDS* 2001;15:71-5.

Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: a cohort study. *AIDS* 2002;16:53-61.

McEvoy GK, ed., 2001. *AHFS Drug Information 2001*, pp 119-25, Bethesda : American Society of Health-System Pharmacists.

Micromedex® Healthcare Series, 2004.

Mootsikapun P and Srikulbutr S. Histoplasmosis and penicilliosis: Comparison of clinical features, laboratory findings and outcome. *Inter J Infect Dis* 2006;10:66-71.

Morse GD, Rosenkranz S, Para MF, et al. Amprenavir and efavirenz pharmacokinetics before and after of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. *Antimicrob Agents Chemother* 2005;49:3373-81.

Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in human. *Clin Pharmacol Ther* 2002;72:1-9.

Moyle GJ. Efavirenz: shifting the HAART paradigm in adult HIV-1 infection. *Expert Opin Investig Drugs* 1999;8:473-86.

Nebert DW. Proposed role of drug-metabolizing enzymes: regulation of steady-state levels of the ligands that effect growth, homeostasis, differentiation and neuroendocrine functions. *Mol Endocrinol* 1991;5:1203-14.

- Nebert DW and Russell D. Clinical importance of the cytochromes P450. *The Lancet* 2002;360:1155-62.
- Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily:update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. *DNA Cell Biol* 1993;12:1-51.
- Nicoll CD. Therapeutic drug monitoring & laboratory reference ranges In: *Current medical diagnosis & treatment 2000*, 39th ed, Tierney LM, McPhee SJ, Papadakis MA, eds, San Francisco, McGraw-Hill companies, 1617-25.
- O'Connor JC, Frame SR and Ladics GS. Evaluation of 15-day screening assay using intact male rats for identifying steroid biosynthesis inhibitors and thyroid modulators. *Toxicol Sci* 2002;69:79-91.
- Okey AB. Enzyme induction in the cytochrome P-450 system. *Pharmacol. Ther* 1990;45:241-98.
- Palella FJ Jr, Delancy KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1998;338:853-60.
- Pilheu JA, Galati MR, Yunis AS, et al. Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin. *Medicina (B Aires)* 1989;49:43-7.
- Phanuphak P. Antiretroviral treatment in resource-poor settings: what can we learn from the existing programmes in Thailand? *AIDS* 2004;18(suppl 3): S33-S38.

Polk RE, Crouch MA, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single dose in healthy men. *Pharmacotherapy* 1999; 19:1378-84.

Porte CL, Graaff-Teulen MA, Colbers EH, et al. Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. *Br J Clin Pharmacol* 2004;58:632-40.

Powderly WG, Landay A and Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? *JAMA* 1998;280:72-7.

Preskron SH. What is the message in the alphabet soup of cytochrome P450 enzymes? *J Pract Psychiatry Behavioral Hlth* 1995;1:237-40. =

Quattrochi LC and Guzelian PS. CYP3A regulation: from pharmacology to nuclear receptors. *Drug Metab Dispos* 2001;29:615-622.

Rodriguez RJ and Acosta D. Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenases. *Drug Metab Dispos* 1997;25:772-7.

Rodriguez RJ and Acosta D. N-deacetyl ketoconazole induced hepatotoxicity in a primary culture system of rat hepatocytes. *Toxicology* 1997a;117:123-31.

Sanglard D and Odds FC. Resistance of *Candida* species to antifungal agents: molecular mechanisms and clinical. *The Lancet infect Dis* 2002;2:73-85.

Sanne I, Herve MM, Hinkle J, et al. Severe hepatotoxicity associated with

nevirapine use in HIV-infected subject. J Infect Dis 2005;191:825-9.

Savini CJ, James CW, Miller JL, et al. Evidence of hypertriglyceridemia in managing HIV patients on efavirenz. J Assoc Nurses AIDS Care 2001;12:95-7.

Sepkowitz KA. Effect of HAART on the natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-30.

Shannon FM and Shannon M. Drug interactions-A review. Clin Ped Emerg Med 2005;6: 93-102.

Siroka Z and Drastichova J. Biochemical Markers of Aquatic Environment Contamination Cytochrome P450 in Fish. A Review. Acta Vet Brno 2004;73: 123-32.

Staszewski SJ, Maraks-Ramirez KT and Tashima A. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl J Med 1999;341:1865.

Supparatpinyo K, Chiewchanvit S, Hirunsri P, et al. *Penicillium marneffe* infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1992;14:871-4.

Teanpaisan R and Nittayananta W. Prevalence of *Candida* species in AIDS patients and HIV-free subjects in Thailand. J Oral Pathol Med 1998;27:4-7.

Thompson DF and Carter JR. Drug-induced gynecomastia. Pharmacotherapy 1993;13:37-45.

Tsang DN, Li PCK, Tsui MS, et al. *Penicillium marneffe* : another pathogen to

consider in patients infected with human immunodeficiency virus. Rev Infect Dis 1991;13:766-7.

Tsui WN, Ma KF and Tsang DN. Disseminated *Penicillium marneffe* infection in HIV-infected subjects. Histopathology 1992;20:287-93.

Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992; 14(1):165-74.

UNAIDS/WHO. Report on the global HIV/AIDS epidemic, December 2005.

US Department of Health and Human Services (US/DHHS), Henry J. Kaiser Family Foundation. <http://hivatis.org>.

van der Meer JW, Keuning JJ, Scheijground HW, et al. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother 1980;6:552-4.

Walsh TJ, Rubin M, Hathorn J, et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Intern Med 1991;151:765-70.

Wang EJ, Lew K, Casciano CN, et al. Interaction of Common Azole Antifungals with P Glycoprotein. Antimicrob Agents Chemother 2002;46:160-5.

Weller IVD and Williams IG. ABC of AIDS : antiretroviral drugs. BMJ 2001;322:1410-2.

WHO. Antiretroviral drugs for the treatment of HIV infection in adults and

adolescents in resource-limited settings. Recommendations for Public Health Approach (2005-2006 Revision).

Wrighton SA, Schuetz EG, Thummel KE, et al. The human CYP3A subfamily: Practical considerations. *Drug Metab Rev* 2000; 32:339-361.

Yan Z and Caldwell GW. Metabolism profile, and cytochrome P450 inhibition and induction in drug discovery. *Cur Top Med Chem* 2001;1:403-25.

Young SD, Britcher SF, Tran LO, et al. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. *Antimicrob Agents Chemother* 1995; 39:2602-2605.

Yuen KH and Peh KK. Simple high-performance liquid chromatographic method for determination of ketoconazole in human plasma. *J Chromatogr B* 1998;715:436-40.